CARRESS Cardiorenal Rescue Study in Acute Decompensated Heart Failure Duke Heart Failure Research Pager: 970-0736.

Slides:



Advertisements
Similar presentations
G. Michael Felker, MD, MHS, FACC Christopher M. O’Connor, MD, FACC
Advertisements

Evaluation and Management of Acute Decompensated Heart Failure
Diuretics or Ultrafiltration?
GUSTO-IV AMI G lobal U se of S trategies T o Open O ccluded Coronary Arteries in AMI.
Girish Singhania N Engl J Med 2012 Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome.
THE IMPORTANCE OF PUBLISHING NEGATIVE FINDINGS Rolofylline, an Adenosine A1 – Receptor Antagonist, in Acute Heart Failure Barry M. Massie et al The New.
EVIDENCE IN THE ED AMOS SHEMESH, MD, PGY-III MARCH 2014 LMNOP in ADHF: Should Lasix Stay in the Acronym?
Beth Davidson DNP, ACNP, CCRN Kristi Hayes MSN, FNP St
Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):
Diuretic Strategies in Patients with Acute Decompensated Heart Failure Diuretic Optimization Strategies Evaluation (DOSE) trial.
Fluid & Electrolyte Imbalance
A Workshop Facilitated by Glenda M. Payne, RN, MS, CNN ESRD Technical Advisor, CMS Regions 4 & 6 Dallas, TX.
MANAGEMENT OF CONTINUOUS HEMODIALYSIS
SMH DKA PROTOCOL Physician Information. Insulin Drip protocol for DKA  Purpose: Quick/Safe management of the patient in DKA  Method: Evidence based.
Presenters for Journal Club: James Cooper Eugenie Shieh Aaron Schueneman Tim Niessen.
Deborah Crawford, APRN-CNS. Speaker for Otsuka Disclosures.
Congestive heart failure
HEMODIALYSIS ADEQUACY HEMODIALYSIS ADEQUACY Laurie Vinci RN, BSN, CNN Laurie Vinci RN, BSN, CNN September 17, 2011 September 17, 2011.
Best Practices in Meeting NPSG 3E-Anticoagulation Requirements MaryAnne Cronin, PharmD Assistant Director of Pharmacy Glen Cove Hospital.
RENAL REPLACEMENT THERAPY
Modified Megestrol The Clinical Trials by : Carolina R. Akib
Coronary Artery Disease Megan McClintock. Coronary Artery Disease Definition Etiology/Pathophysiology Risk Factors –Unmodifiable –Modifiable Signs & symptoms.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Heart Failure With Preserved And Impaired Systolic Left Ventricular Function In ALLHAT JB Kostis, B Davis, L Simpson, H Black, W Cushman, P Einhorn, M.
Loop diuretics VS venous ultrafiltration in cardio-renal syndrome Radek Debiec SHO Renal Medicine LGH Sept 2013.
Copyright 2008 Society of Critical Care Medicine Management of Life- Threatening Electrolyte and Metabolic Disturbances.
Heart Failure, HF CHF develops when plasma volume increases and fluid accumulates in the lungs, abdominal organs (liver especially), and peripheral tissues.
By: Janel Canty RNS (Osborn, 2010). Objectives To understand Hyponatremia To be able to recognize hyponatremia in a clinical setting Be able to apply.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Slide Source: Primary and Other Outcomes: DREAM Rosiglitazone group (n=2635) Placebo group (n=2634)HR (95% CI)p Composite primary.
台大醫院雲林分院 黃道民 Tao-Min Huang NTUH Yun-Lin Branch Acute Cardio-renal Syndrome.
Management of Hypertensive Emergencies. New paradigm in treatment of acute hypertension Acute vascular injury has chronic sequelae Prevention of exaggerated.
The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Brief Protocol Training NIH-NINDS U01 NS NETT CCC U01 NS NETT SDMC U01 NS
BNP for CHF Dr James Young Head, Section of Heart Failure and Cardiac Transplant Medicine Cleveland Clinic Foundation Cleveland, OH.
DVT Prevention and Anticoagulant Management
TUESDAY 19TH OCTOBER2010 CATH LAB PRESENTATION. TAO /ACS study STUDY NUMBER: EFC6204 Randomized, double-blind, triple-dummy trial to compare the efficacy.
Copyright 2008 Society of Critical Care Medicine
SMMART-HF Surgery vs. Medical Treatment Alone for Patients with Significant MitrAl RegurgitaTion & Non-Ischemic Congestive Heart Failure Duke Heart Failure.
Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support SURVIVE-WSURVIVE-W Presented at The American Heart Association Scientific.
Binu George , Heather Bury Critical care Journal Club May 2014
Bicarbonate-Based Solutions in the Management of Acute Kidney Injury Vania Cecilia Prudencio-Ribera, MD 1 ; Universidad Mayor de San Simón, School of Medicine,
APS. Investigators & Sites APS Background Study Hypotheses.
Perioperative Nursing Care
DOSE-AHF Diuretic Optimization Strategies Evaluation in Acute Heart Failure Duke Heart Failure Research Pager:
Angelo L Gaffo Kenneth G Saag Core Evidence 2009:4 25–36
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
RAD Immunosuppression in Heart Transplant Recipients Duke Heart Failure Research Pager:
Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure REMINDER* Gilles Montalescot, Bertram Pitt,
A RandomizEd Trial of ENtERal Glutamine to MinimIZE Thermal Injury: A multicenter Pragmatic RCT (definitive study) Study Sponsor Dr. Daren Heyland Clinical.
ASCEND-HF Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure Duke Heart Failure Research Pager:
Clinical Pharmacology of Diuretics. DIURETIC DRUGS  diuretics are considered to be substances that aid in removing excess extracellular fluid and electrolytes.
신장내과 R4 강혜란 Cardiorenal syndrome (CRS).  Patients with heart failure (HF) who have a reduced GFR -> Mortality ↑  Patients with chronic kidney disease.
  Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, M.D., M.P.H, M.B.A. On behalf.
Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, Marvin A. Konstam, G. Michael.
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Developed by 91 Civil Affairs Presented/modified by 1BCT, 82D ABN DIV
Copyright © 2015 by the American Osteopathic Association.
Acute and Chronic Renal Failure
ACUTE DECOMPENSATD HEART FAILURE AND CARDIORENAL SYNDROME
Change in mean serum creatinine, PAC-guided vs empiric therapy
Expert Insights on Complex Clinical Cases of Edema
MK-0954 PN948 NOT APPROVED FOR USE (date)
Embargoed until 10:45 a.m. CT/11:45 a.m. ET Sunday, Nov. 11, 2018
ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.
TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.
What is the relative risk reduction of ACEi’s/beta blockers for HFrEF?
Maria R. Costanzo et al. JCHF 2016;4:
TRUE-AHF Trial design: Patients with acute decompensated heart failure were randomized in a 1:1 fashion to either early ularitide infusion (within 12 hours)
Decongestive Treatment of Acute Decompensated Heart Failure: Cardiorenal Implications of Ultrafiltration and Diuretics  Benjamin J. Freda, DO, Mara Slawsky,
Presentation transcript:

CARRESS Cardiorenal Rescue Study in Acute Decompensated Heart Failure Duke Heart Failure Research Pager:

Purpose Randomized, controlled, multi-center clinical trial to test the hypothesis that ultrafiltration compared to a stepped pharmacological care approach will result in improved renal function and relief of congestion in patients hospitalized with acute decompensated heart failure (ADHF) and cardiorenal syndrome.

Inclusion Criteria Patients admitted with ADHF who develop cardiorenal syndrome Cardiorenal syndrome:  serum creatinine concentration >0.3 mg/dL in setting of persistent congestion

Interventions Randomized to 1 of 2 treatments Slow continuous venous ultrafiltration Stepped pharmacologic care

Interventions ULTRAFILTRATION (UF) GROUP – Loop diuretics d/c’d during UF – Receive Heparin; goal PTT 2-2.5x normal – UF fluid removal 200cc/hr; continue until signs/symptoms of congestion optimized – Patients randomized to UF group must be transferred to 7300 unit to receive treatment STEPPED PHARMACOLOGIC GROUP – IV diuretics used to address signs/symptoms of congestion – Completed when volume status optimized – Algorithm by Heart Failure Network provided; addresses intensification of diuretics and use of vasodilators and inotropes

Nursing Roles Ensure fluid restriction and 2gm Na diet as ordered Weigh patients before treatment and daily qAM Record I&O Administer study drugs according to CPOE orders

Nursing Roles For patients randomized to UF arm: – ELC* + 18 gauge IV – Heparin protocol; start when PTT – Hold diuretics – UF removal rate 200cc/hr – VS q15 min x1 hr, q min x4 hr, q 4 hrs – Secure and flush post treatment policy *ELC = extended-length catheter

Outcomes Why is this study being done? To look at the safety and efficacy of UF for treatment of persistent congestion and cardiorenal syndrome as measured by: – Change in serum creatinine AND weight – Treatment failure – Change in electrolytes – % achieving clinical decongestion – Total net fluid loss